SCHEDULE: Lincoln Alternative Strategies Discloses 14.46% Stake in Calidi Biotherapeutics

Lincoln Alternative Strategies LLC has reported a 14.46% beneficial ownership stake in Calidi Biotherapeutics, Inc., holding 730,000 shares of common stock.

Summary

• Lincoln Alternative Strategies LLC reported beneficial ownership of 730,000 shares of Calidi Biotherapeutics, Inc. common stock.
• This represents 14.46% of the issuer's common stock outstanding.
• The beneficial ownership percentage is based on 5,049,210 shares of common stock issued and outstanding as of August 20, 2025.
• The securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake is generally a positive signal, indicating confidence from a sophisticated investor. The explicit statement that the investment is not for control purposes suggests a passive, long-term view.

Positives

• A significant institutional investor, Lincoln Alternative Strategies LLC, has taken a substantial stake in Calidi Biotherapeutics, indicating potential confidence in the company's future.
• The filing explicitly states the securities were not acquired for the purpose of changing or influencing control, suggesting a passive investment.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Industry Context

The disclosure of a significant stake by an alternative strategies firm like Lincoln Alternative Strategies LLC in a biotherapeutics company can signal institutional interest in the biotechnology sector, particularly in companies with promising pipelines or strategic positions. Such investments often reflect a belief in the long-term growth potential of the company, aligning with broader trends of increased capital allocation towards innovative healthcare and life sciences firms.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership and does not contain information comparable to industry performance benchmarks or specific project results. It simply reports an ownership stake, which is a common occurrence for institutional investors exceeding the 5% threshold in publicly traded companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a substantial stake could be viewed positively, potentially increasing investor confidence and attracting further institutional interest.
• Company Management: The presence of a large, passive institutional investor may provide a degree of stability and validation for the company's current strategy.

Next Steps

• The filing does not specify any immediate next steps for Calidi Biotherapeutics, Inc. or Lincoln Alternative Strategies LLC beyond the regulatory disclosure.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a substantial, passive stake in Calidi Biotherapeutics. While this is generally a positive signal of confidence, the filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily confirms an existing ownership structure. Investors should 'hold' and await further operational updates or financial results to make a more informed decision, while acknowledging the positive signal from institutional interest.

Keywords

Calidi Biotherapeutics, Lincoln Alternative Strategies, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology Investment, Institutional Investor